<html>
<head>
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
</head>
<body text="#000000" bgcolor="#f9f9fa">
<div class="header reader-header reader-show-element"> <a
class="domain reader-domain"
href="https://www.geertvandenbossche.org/post/c-19-pandemia-quo-vadis-homo-sapiens">geertvandenbossche.org</a>
<h1 class="reader-title">C-19 Pandemia: Quo vadis, homo sapiens?</h1>
<div class="meta-data">
<div class="reader-estimated-time" dir="ltr">34-43 minutes</div>
</div>
</div>
<hr>
<p id="viewer-foo"><span><strong>1. Summary:</strong></span></p>
<p id="viewer-4nkaa"><span>The WHO’s mass vaccination program has
been installed in response to a <em>public health emergency of
international concern</em>. As of the early days of the mass
vaccination campaigns, at least a few experts have been warning
against the catastrophic impact such a program could have on
global and individual health. Mass vaccination in the middle of
a pandemic is prone to promoting selection and adaptation of
immune escape variants that are featured by increasing
infectiousness and resistance to spike protein (S)-directed
antibodies (Abs), thereby diminishing protection in vaccinees
and threatening the unvaccinated. This already explains why<u>
the WHO’s mass vaccination program is not only unable to
generate herd immunity (HI) but even leads to substantial
erosion of the population’s immune protective capacity.</u> As
the ongoing universal mass vaccination program will soon promote
dominant propagation of highly infectious, neutralization escape
mutants (i.e., so-called ‘S Ab-resistant variants’), naturally
acquired, or vaccinal neutralizing Abs, will, indeed, no longer
offer any protection to immunized individuals whereas high
infectious pressure will continue to suppress the innate immune
defense system of the nonvaccinated. This is to say that every
further increase in vaccine coverage rates will further
contribute to forcing the virus into resistance to neutralizing,
S-specific Abs. Increased viral infectivity, combined with
evasion from antiviral immunity, will inevitably result in an
additional toll taken on human health and human lives. Immediate
action needs, therefore, to be taken in order to dramatically
reduce viral infectivity rates and to prevent selected immune
escape variants from rapidly spreading through the entire
population, whether vaccinated or not.<b> This first critical
step can only be achieved by calling an immediate halt to the
mass vaccination program and replacing it by widespread use of
antiviral chemoprophylactics while dedicating massive public
health resources to scaling early multidrug treaments of
Covid-19 disease. </b><br>
</span></p>
<p><span><br>
</span></p>
<p><span>[...]<br>
</span></p>
<br>
<br>
<div id="comp-km7ty6lj" class="_1Q9if" data-testid="richTextElement"><font
size="-2">Geert Vanden Bossche (DVM, PhD)</font></div>
<div class="_1Q9if" data-testid="richTextElement"><font size="-2"><br>
</font></div>
<div id="comp-km7ty6mi" class="_1Q9if" data-testid="richTextElement"><font
size="-2">Geert Vanden Bossche received his DVM from the
University of Ghent, Belgium, and his PhD degree in Virology
from the University of Hohenheim, Germany. He held adjunct
faculty appointments at universities in Belgium and Germany.
After his career in Academia, Geert joined several vaccine
companies (GSK Biologicals, Novartis Vaccines, Solvay
Biologicals) to serve various roles in vaccine R&D as well
as in late vaccine development. Geert then moved on to join the
Bill & Melinda Gates Foundation’s Global Health Discovery
team in Seattle (USA) as Senior Program Officer; he then worked
with the Global Alliance for Vaccines and Immunization (GAVI) in
Geneva as Senior Ebola Program Manager. At GAVI he tracked
efforts to develop an Ebola vaccine. He also represented GAVI in
fora with other partners, including WHO, to review progress on
the fight against Ebola and to build plans for global pandemic
preparedness. Back in 2015, Geert scrutinized and questioned the
safety of the Ebola vaccine that was used in ring vaccination
trials conducted by WHO in Guinea. His <a
href="https://37b32f5a-6ed9-4d6d-b3e1-5ec648ad9ed9.filesusr.com/ugd/28d8fe_485cd4e01c4f41219253ff69cd8d761e.pdf"
target="_blank">critical scientific analysis and report</a> on
the data published by WHO in <a
href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61117-5/fulltext"
target="_blank" rel="noopener">the Lancet</a> in 2015 was sent
to all international health and regulatory authorities involved in
the Ebola vaccination program. After working for GAVI, Geert
joined the German Center for Infection Research in Cologne as
Head of the Vaccine Development Office. He is at present
primarily serving as a Biotech/ Vaccine consultant while also
conducting his own research on Natural Killer cell-based
vaccines.</font></div>
<p><span></span></p>
</body>
</html>